Global Blood Therapeutics, Inc. was delisted on Oct 5, 2022; its insiders filed their last Form 4 on Oct 6, 2022; 247 institutions reported holding it in 13F filings for Q3 2022, worth $4.67B in total; Soros Fund Management was the only superinvestor holding it.
SEC filings
10-K, 10-Q, 8-K, 20-F and 40-F reports Global Blood Therapeutics, Inc. filed with the SEC, newest first.
Livermore lists each filing's form, 8-K items and dates only. To read a filing, open it on SEC.gov; an 8-K's press release or other attachments, such as exhibit 99.1 for Item 2.02, are in the filing index.
SEC filings by Global Blood Therapeutics, Inc.
Filed
Form
8-K items
Period
Document
Filing index
Oct 5, 2022
8-KCurrent report
1.01Item 1.01: Entry into a material definitive agreement1.02Item 1.02: Termination of a material definitive agreement2.01Item 2.01: Completion of an acquisition or disposition of assets2.04Item 2.04: Event that accelerates or increases a financial obligation3.01Item 3.01: Notice of delisting or failure to meet a listing rule; transfer of listing3.03Item 3.03: Material modification to the rights of security holders5.01Item 5.01: Change in control of the company5.02Item 5.02: Departure or appointment of directors or officers; executive pay arrangements5.03Item 5.03: Amendment to the articles of incorporation or bylaws; change in fiscal year9.01Item 9.01: Financial statements and exhibits
1.01Item 1.01: Entry into a material definitive agreement5.03Item 5.03: Amendment to the articles of incorporation or bylaws; change in fiscal year8.01Item 8.01: Other events9.01Item 9.01: Financial statements and exhibits
1.01Item 1.01: Entry into a material definitive agreement2.03Item 2.03: New direct financial obligation, such as new debt or an off-balance-sheet obligation3.02Item 3.02: Unregistered sale of equity securities9.01Item 9.01: Financial statements and exhibits
1.01Item 1.01: Entry into a material definitive agreement2.03Item 2.03: New direct financial obligation, such as new debt or an off-balance-sheet obligation
